Ixabepilone: A new antimitotic for the treatment of metastatic breast cancer

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1252-1261

  Bhushan, Shriya ^a   Walko, Christine M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

BMS 247550; Breast cancer; Epothilones; Ixabepilone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CORTICOSTEROID; CREMOPHOR; CYCLOSPORIN; CYTOCHROME P450 3A4; DIPHENHYDRAMINE; ESTRAMUSTINE PHOSPHATE; GEMCITABINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IXABEPILONE; IXEMPRA; PACLITAXEL; RANITIDINE; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE LIVER FUNCTION RELATION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EPOTHILONES; HUMANS;

EID: 50349084470     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L058     Document Type: Article

References (31)

1. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule stabilizing agent with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
2. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 2004;305:866-9.
3. Product information. Ixempra (ixabepilone). New York: Bristol-Myers Squibb, October 2007.
4. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
5. Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 2008;61:751-8. Epub 27 Jun 2007.
6. Aghajaniam C, Burris HR, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082-8.
7. Dickson N, Peck R, Wu C, Burris H. Ixabepilone given weekly in patients with, advanced malignancies: final efficacy and safety results of a phase I trial (abstract 2040). ASCO Annual Meeting Proceedings Part 1. 2006;24(suppl):18S.
8. Zhuang S, Agrawal M, Edgerly M, et al. Aphase 1 clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8.
9. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73.
10. Hensley ML, Dizon D, Derosa F, et al. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs 2007;25:335-41.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
12. Low J, Wedam S, Lee J, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
13. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
14. Perez E, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
15. Denduluri N, Low J, Lee J, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7.
16. Galsky M, Small E, Oh W, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
17. Hussain M, Tangen C, Lara PJ, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractojry prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9.
18. Vansteenkiste J, Lara PJ, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55.
19. Whitehead R, McCoy S, Rivkin S, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006;24:515-20.
20. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
21. Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second-line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106:58-62.
22. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300-6.
23. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268: 1051-6.
24. Cardinal Health. www.cardinal.com (accessed 2008 Jul 14).
25. Roche H, Perez EA, Llombart-Cussac A, et al. Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): data from neoadjuvant and metastatic breast cancer (MBC) trials (abstract 256P). Ann Oncol 2006;17:S9.
26. Sessa C, Perotti A, Lladò A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 2007;18:1548-53.
27. Mok T, Choi E, Yau D, et al. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology 2006;71:292-6.
28. Rubin E, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120-9.
29. Beer T, Higano C, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565-70.
30. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80.
31. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner R. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006; 45:7942-8.